AIM ImmunoTech Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.9M
- Price
- $0.2584
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.09%
- Volume
- 877.3K
About
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Quick stats
Shares outstanding30.4M
Computed float27.3M
Float / shares89.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000946644
Websitehttps://aimimmuno.com
AI Summary
AI-generated1/50
minorbullishother
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
AIM ImmunoTech CEO Thomas K. Equels published an op-ed in Breaking Defense arguing that biodefense should be treated as a core component of military force protection rather than just a public health response.
The article highlights the potential of Ampligen as a broad-spectrum antiviral, citing preclinical research at USAMRIID where a treated cohort showed 100% survival in a lethal Ebola mouse model compared to 100% mortality in controls.
Equels advocates for the proactive evaluation and stockpiling of medical countermeasures like Ampligen through FDA-regulated pathways before biological threats create operational emergencies.